谁真正受益于EGFR突变NSCLC的第一线强化?
Michele Maffezzoli1,2,3, Jason Lau4, Samuel Justin4
1Department of Medicine and Surgery, University Hospital of Parma - Medical Oncology Unit, University of Parma, Parma, Italy. michele.maffezzoli@unipr.it.
Current oncology reports
|November 1, 2025
概括
使用奥西默蒂尼布加上化疗或阿米万塔-拉泽蒂尼布的第一线治疗强化改善了EGFR突变的晚期非小细胞肺癌 (NSCLC) 的整体存活率. 然而,由于毒性增加和对生活质量的影响,需要仔细选择患者.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 临床试验 临床试验
背景情况:
- 对于具有常见EGFR突变的晚期非小细胞肺癌 (NSCLC) 的标准一线治疗方法是 osimertinib.
- 最近的III期试验 (FLAURA2,MARIPOSA) 显示,随着一线治疗强化策略的实施,整体存活率有所改善.
研究的目的:
- 批判性地评估治疗加剧是否应该成为EGFR突变晚期NSCLC的新标准护理.
- 确定特定的患者亚组,他们可能从前期组合疗法中获益最多.
主要方法:
- 最近的第三阶段临床试验 (FLAURA2, MARIPOSA) 的综述.
- 对强化治疗方案的疗效和安全数据的分析.
- 评估对生活质量和现实世界适用性的潜在影响.
主要成果:
- 高风险子组 (例如,脑/肝转移,特定突变,可检测的ctDNA) 显示从前期组合中获得更大的益处.
- 强化疗法增加了严重不良事件和停止治疗的发生率,影响了耐受性和生活质量.
- 逐渐发展的后进展策略和新兴疗法 (ADC) 可能会影响长期结果.
结论:
- 治疗强化提供了生存益处,但需要仔细选择患者来管理毒性并保持生活质量.
- 基于临床和分子标记的个性化治疗决策对于将试验益处转化为常规实践至关重要.
- 未来的研究应该专注于确定生物标志物,以实现最佳的患者分层和改善毒性管理.
关键词:
在前面和后面的朋友.化疗 化疗是一种化学疗法.欧洲农业基金会 (EGFR) 是一个基金.强化 强化 强化拉泽蒂尼布 (Lazertinib) 是一种药物.在NSCLCLC中,我们可以看到.奥西默蒂尼布 (Osimertinib) 是一种药物.更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
相关概念视频
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K